SynthesisFrontiers in medicine2025
Effectiveness and safety of Maxing Shigan Decoction for community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of traditional Chinese medicine decoctions combined with conventional therapy for pediatric asthma: a network meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Adjunctive Chaihu Guizhi Tang combined with Maxing Shigan Tang and short-term clinical recovery in hospitalized older adults with community-acquired pneumonia: a prospective non-randomized controlled study.Frontiers in medicine · 2026Article
- Integrative Traditional Chinese Medicine Strategies for Refractory Mycoplasma Pneumonia in Children: Clinical Challenges, Mechanisms, and Evidence-Based Insights.Infection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Community-acquired pneumonia (CAP) is an acute lung infection disease with high morbidity and mortality. The treatment of CAP has become more and more challenging due to the gradual increase of antibiotic resistance and adverse events. Relevant evidence indicates that Maxing Shigan Decoction (MXSG) may play a unique therapeutic advantage. Our aim is to evaluate the overall effectiveness and safety of MXSG for CAP. Methods: Eight databases (PubMed, Embase, the Cochrane Library, CNKI, Wanfang, VIP, Yiigle, and Sinomed) were searched from their inception to January 20, 2025. Randomized controlled trials evaluating the effectiveness and safety of MXSG alone or in combination with conventional western medicine (WM) for CAP were included. We conducted meta-analysis by RevMan 5.4 software or just performed qualitative analysis. Results: We included 81 RCTs with 6682 participants in total. Compared with western medicine (WM) alone, MXSG plus WM showed a more beneficial effect on reducing the duration of fever (MD = -1.58 days, 95% CI: -1.88 to -1.29, Conclusion: Moderate or low certainty of evidence suggested that compared with WM alone, MXSG combined with WM may have potential effectiveness on relieving the clinical symptoms, promoting the absorption of lung inflammation, improving lung function, and reducing hospitalization length with a good safety for patients with CAP. In the future, high-quality double-blind RCTs should be required to confirm the effectiveness and safety on CAP. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023404693, identifier CRD42023404693.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.